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The Nakuru eye disease cohort study:
methodology & rationale
Andrew Bastawrous1*, Wanjiku Mathenge3,4, Tunde Peto2, Helen A Weiss5, Hillary Rono6, Allen Foster1,
Matthew Burton1,2 and Hannah Kuper1,7
Abstract
Background: No longitudinal data from population-based studies of eye disease in sub-Saharan-Africa are available.
A population-based survey was undertaken in 2007/08 to estimate the prevalence and determinants of blindness
and low vision in Nakuru district, Kenya. This survey formed the baseline to a six-year prospective cohort study to
estimate the incidence and progression of eye disease in this population.
Methods/Design: A nationally representative sample of persons aged 50 years and above were selected between
January 2007 and November 2008 through probability proportionate to size sampling of clusters, with sampling of
individuals within clusters through compact segment sampling. Selected participants underwent detailed ophthalmic
examinations which included: visual acuity, autorefraction, visual fields, slit lamp assessment of the anterior and
posterior segments, lens grading and fundus photography. In addition, anthropometric measures were taken and
risk factors were assessed through structured interviews. Six years later (2013/2014) all subjects were invited for
follow-up assessment, repeating the baseline examination methodology.
Discussion: The methodology will provide estimates of the progression of eye diseases and incidence of blindness,
visual impairment, and eye diseases in an adult Kenyan population.
Keywords: Cohort study, Longitudinal, Eye disease, Africa, Kenya, Cataract, Glaucoma, Age related macular
degeneration, Diabetic retinopathy, Refractive error, Incidence, Progression
Background
The most recent global estimates suggest 285 million
people worldwide are visually impaired, of whom, 39
million are blind [1]. The WHO defined Africa region
has 26 million people with visual impairment (VI) of
whom 6 million are blind. The continent also has the
greatest disparity between numbers blind and number
of ophthalmologists per million people [2], and therefore
the greatest need for scaling up services.
In recent years several cross-sectional surveys have
been undertaken across Africa to estimate prevalence
and causes of blindness [3-16]. Whilst this information
has been vital in planning services where resources and
provision of healthcare are limited, data on incidence
and rates of progression of eye disease are needed to
allow long-term planning. To date, no longitudinal,
population-based studies of eye disease have been under-
taken in Africa, and there have been only ten worldwide,
predominantly in high-income settings (Table 1) [17-26].
The current study was undertaken in Nakuru district
(now Nakuru County), which is the main district of Kenya’s
largest province, the Rift Valley and has a population of
1.6 million. Nakuru district is broadly representative of
Kenya in terms of ethnic diversity and economic activities.
In 2004, a Rapid Assessment of Avoidable Blindness
(RAAB) was completed in Nakuru district, to estimate
the prevalence and causes of avoidable blindness and VI
in the population of those 50 years and over [7]. A subse-
quent more comprehensive study was planned in the same
region as a consequence of this survey to estimate causes
and risk factors for those with visual impairment as well
as those with non-visually impairing eye disease, with a
particular focus on posterior segment eye disease [6].
Fieldwork was carried out in 2007 and 2008, during
the course of which 4414 participants (a response rate of
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88.1%) aged 50 years and above underwent ophthalmic
and/or general examinations.
The prevalence of blindness and visual impairment
[6], glaucoma, age-related macular degeneration (AMD)
[27], diabetic retinopathy (DR), cataract, refractive error
(RE) [28,29] and cardiovascular diseases [30,31] were
assessed. This 2007/08 survey forms the baseline to co-
hort described here.
The overall aim of this cohort is to estimate the inci-
dence, progression and risk factors for the development
of blindness/visual impairment and their leading causes
in a Kenyan adult population.
Objectives
Incidence
To estimate the age- and sex- specific incidence of visual
impairment (VA < 6/12) and blindness (VA < 3/60) (all
causes) in a Kenyan adult population.
To estimate the age- and sex- specific incidence of cata-
ract, RE, glaucoma, AMD and DR.
Causes & risk factors
To identify the causes and risk factors for incident visual
impairment and blindness from specific diseases investigated
(specifically focusing on demographic, anthropometric,
behavioural, and vascular risk factors).
Progression
To estimate the risk of progression of Cataract, RE, Glau-
coma, AMD and DR among cases detected at baseline.
Treatment & progression outcome
To describe the outcome of treatment for cataract, RE,
glaucoma or DR among cases detected at baseline.
To describe the progression of untreated eye disease
among cases detected at baseline.
Table 1 Population-based cohort studies of eye disease (not exhaustive)
Study Location Year commenced Years of follow up No of participants Reference*
Beaver Dam Eye Study USA 1988 Baseline 4926 [17]
5 3684
10 2764
15 2119
Blue Mountain Eye Study Australia 1992 Baseline 3654 [18]
5 2335
10 1952
Rotterdam Study Netherlands 1990 Baseline 6418 [19]
2 4953
6.5 3406
11 2387
Copenhagen City Eye Study Denmark 1986 Baseline 946 [20]
14 359
Barbados Eye Study Barbados 1987 Baseline 4631 [21]
4 3427
9 2793
Pathologies Oculaires Liees a L’Age France 1995 Baseline 2584 [22]
3 1642
Melbourne Visual Impairment Project Australia 1992 Baseline 5147 [23]
5 3271
Hisayama Study Japan 1998 Baseline 1482 [24]
5 961
9 (1401>40 yrs)
Reykjavik Eye Study Iceland 1996 Baseline 1045 [25]
5 846
Los Angeles Latino Eye Study USA 2000 Baseline 6357 [26]
4 4658
*Only one reference per study given.
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Methods/Design
This paper describes the definitions, eligibility criteria,
follow-up procedures, visual acuity (VA) measurements,
anthropometry and clinical examination procedures adopted
for the study.
Baseline study population - sample size
The sample size of 5000 participants required for the
baseline survey was calculated based on an expected
prevalence of VA < 6/12 in the better eye due to posterior
segment eye diseases (PSED) of 3.0% among those
aged ≥50 years, a required precision of 0.5% (i.e. a
95% confidence interval [CI] of 2.5%-3.5%), a design
effect of 1.5, and a response rate of 90%. (Epi Info 6.04,
Centers for Disease Control and Prevention, Atlanta, GA).
We selected 100 clusters each of 50 participants.
Sampling strategy and recruitment
Recent census data for Kenya were not available [32],
and therefore electoral role lists that were renewed in
2006 in preparation for the 2007 general elections were
used as the sampling frame for this baseline survey.
The population size was updated for the year 2007
using a population growth rate of 2.7% per year [33].
One hundred clusters were selected with a probability
proportional to the size of the population (Figure 1). A
cluster was defined as the area served by the polling
station.
Households were selected within clusters using a modi-
fied compact segment sampling method [34]. Each cluster
was divided into segments so that each segment included
approximately 50 people aged ≥ 50 years. For instance,
if a cluster included 200 people aged ≥ 50 years then it
was divided into four segments. One of the segments
was chosen at random by drawing lots and all households
in the segment were sequentially sampled, until 50 people
aged ≥ 50 years were identified. An eligible individual was
defined as someone aged ≥ 50 years living in the house-
hold for at least three months in the previous year. Age
was determined using the subject’s testimony, national
identity cards and a calendar of historic events. If the
segment did not include 50 people aged ≥ 50 years then
another segment was chosen at random and sampling
continued until 50 were reached. If after enumerating
individual number 49 the next household had more than
one person aged ≥50 all were enumerated and invited for
examination.
Baseline findings
In total, 4381 participants underwent complete (ophthalmic
and general) examination at baseline across 100 clusters.
The prevalence of blindness was 1.6% (95% CI: 1.2-2.1%) [6].
Follow-up
A pilot follow up retraced 438 participants from 10 of the
100 clusters in 2008, a mean of 1.5 years from baseline,
and 408 (79%) were successfully retraced to give an
estimated 4.2% loss per year.
Retracing at follow-up - advance team
Approximately one week before the follow-up examination
clinic was planned for a given cluster, a field officer studied
the maps of the village and made phone contact with the
village chief or guide to arrange the visit. At the planning
visit a list of study participants were given to the chief and
a local village guide was recruited to assist location of the
study participants. At this visit the examination site was
established and identification of amenities such as electri-
city, water and road access were made. Two days prior to
the clinic, the field officer reminded chiefs of the visit by
phone and notified them and the guide of the advance
team’s arrival.
On the day prior to the examination clinic, the Advance
Team visited homes of baseline participants and confirmed
their identity using National Identity cards. The two ad-
vance teams comprised of one nurse, one field officer and a
driver or public transport. During this visit they performed
the following duties:
○ Located individuals with assistance from the guide,
phone numbers when available and previously
recorded GPS locations using a Garmin Oregon
450 Satellite Navigation device.
○ Explained details of the exam and obtain written/
thumb print informed consent for examination
○ Informed selected participants about location and
time for examination
Figure 1 Map showing the 100 study locations in the Nakuru
County, Kenya.
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Registration
On the examination day, the advance team confirmed
the identity of participants against their records from
the previous day and against data from baseline (age,
date of birth, name, and identity cards). Each participant
was given a questionnaire, which was completed by the
examiners as they move from station to station.
Examination procedures
Examinations were performed as per baseline unless
otherwise indicated in Table 2.
Details of each examination station are provided below
including differences, if there were any, between baseline
and follow-up.
Anthropometry
A nurse performed and recorded measures of participants:
height; weight; waist and hip circumference, and three
measures of blood pressure, each 5 minutes apart. In
addition, at follow-up, bioimpedence (Tanita Segmental
Body Composition Monitor) was performed.
At baseline, capillary blood was taken from all par-
ticipants for random blood glucose and cholesterol.
At follow-up, no blood for cholesterol was collected
and in addition, subjects with a random blood sugar
greater than 11.1 mmol/L (IDF guidance at time of
baseline study), those with known diabetes (regardless
of random measure), evidence of diabetic retinopathy
on retinal imaging and a subset (chosen randomly
within each cluster) with random glucose between 7-
11 mmol/L had an additional capillary blood HbA1c (A1C
Now+, Bayer).
Interview
An interviewer performed the structured interview in
the participant’s preferred language covering i) demo-
graphic details including; name, year of birth, ethni-
city and education level; ii) past medical and ocular
history including medical or ophthalmic medication
or surgery and relevant family history; iii) relevant
risk factors including; smoking and tobacco consump-
tion and alcohol intake; iv) socioeconomic status
based on job, housing conditions, ownership of ma-
terial goods and livestock which is translated in to a
score based on previous work in the same population
[35]. (See Additional file 1: Appendix for Question-
naire/Data Entry Booklet).
Visual acuity
A clinical officer determined whether the study participant:
a) Attends wearing distance correction glasses
b) Owns distance correction glasses but failed to
bring them
c) Does not have any distance glasses
d) Routinely uses reading glasses
e) Attends wearing aphakic glasses
Visual acuity (VA) was measured using a back-illu-
minated modified LogMAR reduced tumbling E chart
[36,37], which has been used in previous population
based studies [38,39].
Autorefraction
All subjects, regardless of VA underwent autorefraction
using the Topcon® Auto refractor RM8800 at baseline
and the hand held SureSight autorefractor (Welch Allyn)
at follow-up, following manufacturers guidelines. Any sub-
ject recording an acuity of ≤24 optotypes, <6/9 equivalent
(with or without glasses) underwent best corrected visual
acuity. The refraction measure recorded for each eye was
mounted in the trial frames using trial lenses (rounded
up or down to the nearest 0.25 diopters). Visual acuity was
then re-measured to give an estimate of the “corrected
visual acuity” in each eye individually. When autorefraction
results were not available, the pinhole method was used
to estimate corrected visual acuity. A subset of partici-
pants also underwent manual refraction by a visiting
optometrist for five clusters to validate the accuracy of
the autorefractor.
Visual field assessment
At baseline, all individuals with suspect or abnormal discs
on clinical examination underwent automated visual field
testing. The Humphrey® Field Analyzer II - 720i series
(Carl Zeiss Ophthalmic Systems, Inc.) was used. A suspect
or abnormal disc was defined as a vertical cup/disc ratio
(VCDR) of 0.7 or above; optic disc cupping asymmetry
between the eyes of more than 0.2 VCDR; or any other
abnormal features. A random sample of five individuals
per cluster (10%) also underwent visual field testing to
provide normative data.
Participants performed the Swedish Interactive Thresh-
olding Algorithm (SITA) STANDARD 24–2. SITA Fast
was used to determine the threshold level in all partici-
pants having visual field analysis. Appropriate corrective
lenses for refractive errors were used when needed. An
automated fixation monitor was used throughout. If the
SITA fast test was reliable (following manufacturers guide-
lines) the SITA standard test was performed. If the SITA
fast was unreliable then this was repeated once. If it
remained unreliable then no further testing was done.
At follow-up, a different strategy for visual field testing
was used: All subjects with VA equivalent to > =6/60
Snellen underwent automated visual field testing by a
trained visual field technician using the Henson 8000
Visual Field Analyser (TopCon, Inc.) The multiple stimu-
lus suprathreshold test was used following manufacturers
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guidelines (Screening test - 26 test locations). When one
or more spots were missed, the 26-point test was repeated
for that eye. If any missed spots re-occurred on the second
time of testing the test for that eye was extended to 68
test locations. This machine and strategy were used in
preference to the baseline methods due to feedback
from both patient’s and tester at baseline. Patient’s found
the baseline testing protocol difficult to understand and
the time required to complete the test meant only a sub-
sample of the population could be investigated.
Slit lamp biomicroscopy examination
Undilated (anterior segment) and dilated (posterior
segment) slit lamp biomicroscopy examination were
performed on all participants by the study ophthal-
mologists (WM at baseline, AB at follow-up) using a
Table 2 Instruments used at baseline and follow-up for examination, including rationale for change where appropriate
Procedure Baseline Instrument (2007/08) Follow-up instrument
(2013/14)
Rationale for change
Near Vision Test Continuous Text “Read in Style®”
diopter chart
Unchanged N/A
Personal Interview Questionnaire developed by the
survey ophthalmologist (WM)
Questionnaire developed by
the survey ophthalmologist
(AB) see Additional file 1: Appendix
N/A
Weight The Seca 761 Medical Class 4
Scales mechanical ground scale
(Williams Medical Supplies, London)
Tanita Segmental Body
Composition Monitor
Combined weight and bioimpedence
device – approved for medical studies
Bioimpedence Not performed Tanita Segmental Body
Composition Monitor
Combined weight and bioimpedence
device – approved for medical studies
Height Leicester Height Measure
(Stadiometer) (Chasmors Ltd,
London)
SECA Height Measure Better stability on uneven grounds
Waist and Hip
circumference
Chasmors WM02 Body
Tape measure
SECA Measuring tape Availability
Blood pressure Omron® Digital Automatic Blood
Pressure Monitor Model HEM907
Unchanged N/A
Visual Acuity ETDRS LogMAR chart Unchanged N/A
Auto refraction Topcon® Auto refractor RM8800 Welch Allyn SureSight Improved portability
Corrected Visual Acuity Frames and standard
refraction lenses
Unchanged N/A
Undilated eye exam
including imaging (SL-OCT)
Haag-Streit® Slit lamp
BD900 with SL-OCT
Haag-Streit® Slit lamp
BM900 – no SL-OCT
Availability
Tonometry Haag Streit® Goldmann
Applanation tonometer
on above slit lamp
Haag Streit® Goldmann Applanation
tonometer on above slit lamp
N/A
Gonioscopy Not performed Four-mirror non-coupling gonioscopy
lens (Zabby’s)
For glaucoma sub-typing and angle
evaluation in normal population
Visual fields Humphrey Field Analyzer
II -720 i series(Zeiss®)
Henson 8000 Visual Field Analyser
(TopCon, Inc)
Deemed more suitable for
epidemiological data collection
Pupil Dilation Mydriacyl drops (Alcon®) G. Tropicamide 1% + G.
Phenylepherine 2.5% (Minims)
Single units and better shelf life
Blood sugar Accutrend GCT and
test strips (Roche®)
OneTouch Select, Lifescan Availability. Approved for
medical studies
Blood Cholesterol Accutrend GCT and
test strips (Roche®)
Not performed Cost prohibited inclusion
HbA1c Not performed (A1C Now+, Bayer) Increase accuracy of Diabetes Mellitus
diagnosis as participants non-fasted
Examination of anterior
and posterior segments
through a dilated pupil
90D lens and slit lamp(Volk®) Superfield and 60D Lens
(Volk) and Slit Lamp
Study ophthalmologist preference
Retinal Photo Topcon® NW6S Non
Mydriatic camera model
Haag-Streit DRS Retinal Camera Suitability for travel and ease of use.
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Haag-Streit BD 900 Slit Lamp (BM 900 at follow-up)
and Volk condensing lenses (90D at baseline, Superfield
and 66D at follow-up).
Anterior segment
The anterior segment of the eye was assessed for the
presence of signs of trachoma. In addition at follow up
examination included grading of corneal scarring, pte-
rygium, secondary glaucoma, evidence of past or active
uveitis, or evidence of surgery. The angle at baseline
and follow-up was assessed using the Van Herick Test
[40] and direct visualization of the angle using gonioscopy
(performed after intraocular pressure, see below) was
performed at follow-up.
At follow-up, the ophthalmologist using a bright LED
pen torch tested for the Relative Afferent Pupil Defect
(RAPD). RAPD was recorded as present or absent. If
present it was sub-categorised in to “subtle” or “definite”.
Intraocular pressure
Goldmann Applanation Tonometry (GAT) was used to
measure intraocular pressure (IOP). A drop of Proxy-
methacaine and fluorescein (minims) were instilled to each
eye. After 20 seconds the GAT was used in combination
with a slit lamp to measure the IOP in each eye. The GAT’s
calibration was checked as per manufacturers instructions
on a daily basis by the study ophthalmologist, if found to
be inaccurate, the spare GAT was used whilst the original
was returned to the factory for calibration. One reading
was taken from each eye and the GAT was disinfected
between patients.
Gonioscopy
Assessment of the opening angle of participants’ right and
left eyes was made using a four-mirror gonioscopy lens
(Zabbys). This lens does not require coupling fluid and
was chosen to minimize impact on the quality of retinal
photographs. Angles were recorded using standard Shaffer
grading [41] and further classified as “open”, “occludable”
or “closed” based on standard referral criteria. Occludable
angles are defined as: pigmented trabecular meshwork not
visible in 3⁄4 or more of angle circumference in primary
position without manipulation, in presence of low illumin-
ation. If the patient could not cooperate with gonioscopy,
the Van Herick (VH) technique [40] was used for grading.
Dilated slit lamp examination
Pharmacologic dilation of the subject’s pupils was achieved
by using tropicamide 1% (Mydriacyl) with phenylephrine
hydrochloride 2.5% if needed. Dilation was not performed
in subjects deemed at risk of narrow angle closure (inability
to visualise at least 180° of posterior pigmented trabecular
meshwork on non-indentation gonioscopy [42]). At risk
subjects were referred to the Nakuru Eye Unit for prophy-
lactic laser peripheral iridotomies.
Lens
The WHO simplified system for lens grading was used
[43] following standard protocols. The lens was also
examined for position, the presence of hyper mature
(Morgagnian) cataract, and previous lens surgery (aphakic
or pseudophakic). A red reflex lens image was taken when
each participant was having retinal photographs. At
follow-up, pseudophakic participants were assessed for
the presence or absence of posterior capsular opacification
and, if present, whether it entered the visual axis.
Optic disc
The optic nerve head was examined using a 90 Diopter
Lens (Volk) at the slit lamp at baseline and a 66 Diopter
lens (Volk) at follow-up. The clarity of the optic nerve
head was determined and graded as clear, hazy or no
view. Among subjects in whom an adequate view of the
disc was obtained, the VCDR was estimated and recorded
for each eye. Other glaucomatous changes were recorded
and non-glaucomatous characteristics such as optic atro-
phy and optic pits were also recorded.
Macula
The macula was examined using a 90 Diopter Lens (Volk)
at the slit lamp at baseline and a 66 Diopter or Superfield
lens (Volk) at follow-up. The view of the macula was
recorded as clear, hazy or no view. DR was clinically
graded and recorded as absent, non proliferative, prolif-
erative and end stage or maculopathy (macula oedema)
[44]. The presence of drusen, hypo or hyper pigmentation,
dry or geographic atrophy and neovascular changes were
also recorded.
Fundus photography
An Ophthalmic Assistant performed digital photography
of the lens and fundus on all study participants using a
Topcon® NW6S Non Mydriatic camera model at baseline
and DRS Digital Fundus Camera (Haag-Streit) at follow-up.
The study ophthalmologist checked images were of suffi-
cient quality for grading in the absence of prominent media
opacities. An anterior segment co-axial photograph was
taken for lens grading from each eye. Two 45° fundus pho-
tographs were taken in each eye, one optic disc centered
and the other macula centered. Images were then securely
uploaded to the Moorfields Reading Centre for review
and grading for image quality, the presence or absence of
pathology and the severity of pathology when present.
Note: The gold-standard for grading of DR, AMD and
optic disc changes is based on retinal photographs and not
clinical assessment. Clinical examination was performed as
a backup to equipment failure and a comparison of clinical
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and image based grading can be compared in the analysis
stage and factored in the scenario by which a number of
participants only have clinical grading available.
Data management and analysis
A patient record was completed for each participant and
crosschecked for errors by the project field coordinator.
Patient records were scanned to create a digital backup
and then data were entered into an EpiData database (with
built in range and consistency checks) independently by
two data clerks and validated by the study ophthalmolo-
gist to reconcile any differences. Further data cleaning and
all statistical analyses were conducted using STATA 10.0
(StataCorp LP, Texas, USA).
The visual fields PDF print outs and raw data were
sent securely to Moorfields Eye Hospital for grading
along with the fundus and anterior segment images at
baseline and follow-up. All image and visual field data
were backed up on local devices and external hard
drives. All images were first examined for quality and
categorized as excellent, good, fair, borderline and
ungradeable. If the images were ungradeable the clinical
diagnosis was used. For gradable images the retina and
optic disc were reviewed, and a diagnosis made based on
the appearance of the image e.g. diabetic retinopathy,
toxoplasmosis, onchocerciasis, age related macular degen-
eration, myopic fundus, glaucoma, optic atrophy or other
retinal pathology. VCDR was measured and all images
were graded for the absence/presence and stage of DR
and ARMD. The graders graded the images for as many
disease categories as possible, and so if it was feasible to
grade an image for optic disc abnormality but not for
ARMD, then the grader completed the optic disc grading
only. A senior grader verified a random 10% of images
that were graded as normal as well as all abnormal images
to ensure quality assurance. The graders re-graded a ran-
dom selection of images with a minimum of 14-days inter-
val to allow for intragrader reliability to be established.
Definitions used for analysis are detailed in Table 3.
Quality assurance procedures
Training
Inter observer variations (IOV) assessments were per-
formed in the training phase. IOV assessments on anthro-
pometric variables were done by having the two nurses
perform repeat measuring of 50 subjects. IOV of visual
acuity were undertaken by having the ophthalmic clinical
officer (OCO) and ophthalmic nurse repeat measures of
50 subjects (half normal vision and half visual impairment).
IOV of undilated examinations were done by repeat
measure of 50 subjects (half normal vision and half vis-
ual impairment) by a visiting ophthalmologist and study
Table 3 Definitions of disease incidence and progression
Disease Incidence Progression
Definition At risk Cases At risk Cases
Blindness and Visual
Impairment (VI)
Blind: Persons with VA
of ≥3/60 in the better
eye at baseline.
Persons who have VA of <3/60 in the
better eye at follow up who had ≥3/60
in the better eye at baseline
Categorical changes in visual acuity between: Normal;
Mild VI; Moderate VI; Severe VI; Blind, with a minimum
of two line Snellen equivalent change in VA.
Cataract
Persons without evidence
of cataract at baseline
based on WHO simplified
cataract grading systems
Persons with evidence of cataract
at follow-up based on WHO
simplified cataract grading systems
[45] who did not have evidence
at baseline
Persons with evidence
of any grade of cataract
at baseline based on
WHO simplified cataract
grading systems
Persons who increase by
two or more severity grades
in each sub-type of cataract.
Primary open
angle glaucoma
Persons without
glaucoma in either eye at
baseline based on ISGEO
[46] criteria
Persons who develop ISGEO
classification 1, 2 or 3 glaucoma
by the 6-year follow-up point
Glaucoma or glaucoma
suspect case at baseline
Definite, disc or field
progression. See below* [47]
Age-related
macula degeneration
Persons who did not
have any evidence
of AMD at baseline
in both eyes
Persons with evidence
of early, late or specific
AMD lesions
AREDS [48] step 9 or less
(no AMD or early AMD)
at baseline.
2-or-more-step increase in
combined AREDS score from
baseline in persons with gradable
fundus photographs at both
time points.
Diabetic
retinopathy
Persons with diabetes
and free of retinopathy
at baseline and persons
developing DM by
follow up.
Persons with signs of DR
(ETDRS) [49]
Persons with diabetes
and minimal or moderate
DR at baseline
(1) Persons who develop
severe DR by the 6-year
follow-up
CSME and incidence of
proliferative or severe DRϒ (2) Increase by ≥ 3 steps on
the ETDRS Severity Scale or
development of proliferative DR
necessitating photocoagulation
therapy or vitrectomy
*Definite progression will be defined as those with a combination of ≥0.2 VCDR increase in either eye and/or ≥0.2 VCDR asymmetry between the two eyes with a
corresponding progression on the visual field test defined as (TBC – either “expert analysis” or an arbitrary objective measure).
Note: More specific definitions will be provided in subsequent papers.
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ophthalmologist at the beginning of the baseline survey and
again in the middle. IOV of dilated exams were done by
repeat measure of 50 subjects (half normal vision and half
visual impairment) by a visiting ophthalmologist and study
ophthalmologist at baseline. Retraining was done where
IOV scores indicated poor comparability (kappa < 0.5).
At follow-up, four weeks of training in November/
December 2012 was completed for the study team
members on all equipment and study protocols. Three
pilot clusters examining over one hundred people were
completed prior to commencing the study.
Standard Operating Procedures (SOP) detailing follow-
up survey methodology for each examination station were
prepared and read by all study team members. The SOP
was used in training and for reference during fieldwork.
Supervisory visits were made to the field site (HK and
MJB) to monitor practices and ensure standard protocols
were being followed.
Non-responders at follow-up
Participants who were examined at baseline and eligible
for follow-up assessment but who did not attend the
examination clinic were contacted to determine the reason
for their absence. Participants who were not locatable for
the examination were categorized as non-responders and
their reason for absence determined through available
phone contact, neighbors and village guides as, “deceased”,
“moved away”, or “unknown”.
Service provision
All participants identified with treatable disease in the
study were offered appropriate care including free surgery
and transport to the Rift Valley General Provinical Hospital
or St Mary’s mission hospital, Elementita. Specific cases re-
quiring other services were referred to the Kikuyu Eye Unit.
A trained ophthalmic nurse or Ophthalmic Clinical Officer
(OCO) discussed the diagnosis and the treatment options
available to subjects diagnosed with untreatable eye disease.
As well as study participants, non-study attendees were
examined and treated by the study team.
Ethical approval
The study adhered to the tenets of the Declaration of
Helsinki and was approved by the Ethics Committee of
London School of Hygiene and Tropical Medicine at both
baseline and follow-up. Baseline approval was provided by
the Kenya Medical Research Institute and the African
Medical and Research Foundation (AMREF), Kenya at
follow-up. At both phases approval was also granted by
the Rift Valley Provincial Medical Officer and the Nakuru
district Medical Officer of Health. Approval was sought
from the administrative heads in each cluster, usually the
village chief. They were also given a copy of the consent
form to read and pass on to those in the village.
Informed consent
Informed consent was obtained from all participants.
The objectives of the survey and the examination process
were explained to those eligible in the local dialect, in
the presence of a witness. A subject was examined only
after informed consent was obtained. All participants
gave written (or thumbprint) consent to participate.
Discussion
The Nakuru Eye Disease Cohort Study is the first
population-based cohort study of eye disease to have
taken place in Africa. It will provide estimates on the
incidence of blindness and visual impairment, the incidence
and progression of: cataract, refractive error, glaucoma,
ARMD and DR as well other retinal conditions. This data
will be disseminated to eye care providers and programs in
the region to facilitate the provision of eye care services.
Additional file
Additional file 1: Appendix. The Nakuru Eye Disease Cohort Study -
Study Questionnaire 2013.
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